FDA has cleared the Lucica Glycated Albumin-L, a specific intermediate glycemic control marker, for sale in the United States. The test is manufactured by Tokyo-based Asahi Kasei Pharma and sold exclusively by EKF Diagnostics, Cardiff, UK. It delivers a specific quantitative determination of glycated albumin (GA) in serum on compatible clinical chemistry analyzers with open channel capability.
Lucica Glycated Albumin-L offers several advantages:
- It is specific for GA. It does not measure other glycated proteins such as glycated immunoglobulins.
- The test measures both glycated albumin and total albumin in separate reactions.
- Results are expressed as ratio, thus minimizing differences in protein concentrations between patients.
For more information, visit EKF Diagnostics.